☐

Preliminary Proxy Statement

☐

Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(E)(2))

☒

Definitive Proxy Statement

☐

Definitive Additional Materials

☐

Soliciting Material Pursuant to Section 240.14a-11(c) or Section 240.14a-12

No fee required

Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

Title of each class of securities to which transaction applies:    N/A

Aggregate number of securities to which transaction applies:    N/A

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):    N/A

Proposed maximum aggregate value of transaction:    N/A

Total fee paid:    N/A

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Amount Previously Paid:    N/A

Form, Schedule or Registration Statement No.:    N/A

Filing Party:    N/A

Date Filed:    N/A

Where:

Via a live webcast at www.proxydocs.com/ASH

There is no physical location for the Annual Meeting

Items of Business:

(1)     Election of the 9 director nominees named in the accompanying Proxy Statement for one-year terms expiring at the next annual meeting of stockholders and until their successors are duly elected and qualified;

(2)     To ratify the appointment of Ernst & Young LLP as independent registered public accountants for fiscal 2022;

(3)     To vote upon a non-binding advisory resolution approving the compensation paid to Ashland’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion; and

(4)     To consider any other business properly brought before the Annual Meeting

Who Can Vote:

Only stockholders of record at the close of business on December 1, 2021 are entitled to vote at the Annual Meeting or any adjournment of that Annual Meeting.

You can vote in one of several ways:

Visit the website listed on your proxy card or Notice of Internet Availability of Proxy Materials to vote VIA THE INTERNET

Call the telephone number specified on your proxy card or visit the website on the Notice of Internet Availability of Proxy Materials to vote BY TELEPHONE

If you received paper copies of your proxy materials in the mail, sign, date and return your proxy card in the enclosed envelope provided to vote BY MAIL

PROXY SUMMARY

QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING

ASHLAND COMMON STOCK OWNERSHIP OF CERTAIN BENEFICIAL OWNERS

ASHLAND COMMON STOCK OWNERSHIP OF DIRECTORS AND EXECUTIVE OFFICERS OF ASHLAND

PROPOSAL ONE - ELECTION OF DIRECTORS

Board of Directors

Director Nominees

Director Diversity and Tenure

Director Compensation

Stock Ownership Guidelines for Directors

Corporate Governance

Governance Principles

Board Leadership Structure

Oversight of Ashland’s Executive Compensation Program

Compensation Committee Interlocks and Insider Participation

Board’s Role of Risk Oversight

Director Independence and Certain Relationships

Related Person Transaction Policy

Delinquent Section 16(a) Reports

Communication with Directors

Attendance at Annual Meeting

Executive Sessions of Directors

Stockholder Recommendations for Directors

Stockholder Nominations of Directors

Committees and Meetings of the Board of Directors

EXECUTIVE COMPENSATION

Compensation Discussion and Analysis

Compensation Committee Report

Summary Compensation Table

Grants of Plan-Based Awards

Outstanding Equity Awards at Fiscal Year End

Option Exercises and Stock Vested

Pension Benefits

Non-Qualified Deferred Compensation

Potential Payments upon Termination or Change in Control

AUDIT COMMITTEE REPORT

PROPOSAL TWO - RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS

PROPOSAL THREE -  NON-BINDING ADVISORY RESOLUTION APPROVING THE COMPENSATION PAID TO ASHLAND’S NAMED EXECUTIVE OFFICERS

MISCELLANEOUS

Proxy Solicitation

Stockholder Proposals for the 2023 Annual Meeting

Other Matters

APPENDIX A

Use of Non-GAAP Measures and Non-GAAP Reconciliations

Forward-Looking Statements

Date & Time:

January 25, 2022 at 10:30 a.m. (EST)

Place:

Via a live webcast at www.proxydocs.com/ASH

There is no physical location for the Annual Meeting

Record Date:

December 1, 2021

Voting:

Board’s
Recommendations

  Proposal One. The election of 9 director nominees (page 10)

FOR ALL of your
Board’s Director
Nominees

  Proposal Two. Ratification of the appointment of Ernst & Young LLP as independent registered public accountants for fiscal 2022 (page 76)

  Proposal Three. A non-binding advisory resolution approving the compensation paid to Ashland’s named executive officers (page 77)

/ efficacy usability allure integrity profitability^™

(i)

Name

Primary Occupation

 Brendan M. Cummins

Former Consultant to The Valence Group; Former Chief Executive Officer of Ciba Specialty Chemicals

(Chair);

AC

 William G. Dempsey

Former Executive Vice President of Global Pharmaceuticals at Abbott Laboratories

(Chair);

EHS&Q

 Jay V. Ihlenfeld

Former Senior Vice President of 3M Company

 Wetteny Joseph

Executive Vice President and Chief Financial Officer of Zoetis, Inc.

EHS&Q

 Susan L. Main

Senior Vice President and Chief Financial Officer of Teledyne Technologies Incorporated

 Guillermo Novo

Chairman of the Board and Chief Executive Officer

 Jerome A. Peribere

Former President and Chief Executive Officer of Sealed Air Corporation

 Ricky C. Sandler

Founder and Chief Executive Officer/Chief Investment Officer of Eminence Capital

G&N

 Janice J. Teal

Former Group Vice President and Chief Scientific Officer for Avon Products Inc.

AC – Audit Committee

Comp – Compensation Committee

/ efficacy usability allure integrity profitability^™

(ii)

Ashland signed a definitive sale agreement with Arkema on August 31, 2021 to sell the Performance Adhesives business for $1.65 billion. Expected net proceeds are $1.2 to $1.3 billion and the transaction is expected to close in the March quarter of 2022.

In September 2021, Ashland established a renewable annual trust for environmental remediation (Environmental Trust) that Ashland determined is restricted for ongoing and future environmental remediation and related litigation costs. The initial funding of this trust was $90 million.

In September 2021, under the 2018 stock repurchase program, Ashland announced that it entered into an accelerated share repurchase agreement (2021 ASR Agreement). Under the 2021 ASR Agreement, Ashland paid an initial purchase price of $450 million and received an initial delivery of 3.9 million shares of common stock during September 2021. The program is expected to terminate by March 2022, resulting in a final share repurchase transaction.

In April 2021, Ashland completed its acquisition of the personal care business of Schülke & Mayr GmbH (Schülke), a portfolio company of the global investment organization EQT. Ashland has included the purchase of this business within the Personal Care and Household reporting segment. The all-cash purchase price of Schülke was $312 million. The completion of the acquisition strengthens the profitable growth of the personal care and household business segment, enhances the specialty ingredients solutions and expends the biotechnology and microbiology technical competencies.

Operating income of $181 million in 2021 compared to a loss of $463 million in 2020. The 2020 loss was driven by a $530 million goodwill impairment charge associated with Ashland’s business realignment during fiscal 2020 and is also included in the loss from continuing operations and net loss for fiscal 2020 discussed below.

Income from continuing operations of $173 million in 2021 compared to a loss of $555 million in 2020.

Net income of $220 million in 2021 compared to a loss of $508 million in 2020.

Adjusted EBITDA of $495 million in 2021 compared to $449 million in 2020.

/ efficacy usability allure integrity profitability^™

(iii)

role, including the scope and complexity of responsibilities;

experience and capabilities;

contributions or responsibilities beyond the typical scope of the role;

individual performance and internal equity; and

competitive compensation opportunities as reflected in compensation provided by our peers and other competitors for similar executive talent.

The Compensation Committee increased the base salaries of the NEOs other than Mr. Willis and Dr. Musa to recognize their contributions and further position them closer to the median of our peer group.

Other than for Mr. Novo, Mr. Willis, Dr. Musa, and Mr. Boni annual target incentive opportunities also increased for the NEOs.

Long-term target incentive opportunities also increased for all NEOs except for Mr. Novo, Mr. Willis and Dr. Musa who were already market competitive along with Mr. Boni.

For the fiscal 2021 performance period, the Compensation Committee used Adjusted EBITDA and EBTDA margin % along with a workplace EHS/safety modifier as annual incentive metrics. These are non-GAAP measures and are reconciled to the applicable GAAP measurements in Appendix A.

The Compensation Committee used adjusted Return on Net Assets (RONA) and relative Total Shareholder Return as a three-year performance metric for the long-term incentive performance plan. Adjusted RONA is a non-GAAP measure and will be reconciled when the long-term incentive performance plan is scored.

/ efficacy usability allure integrity profitability^™

(iv)

What matters will be voted on at the Annual Meeting?

A:     

   (1)    

Election of 9 directors to your Board of Directors to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified. Your Board unanimously recommends that you vote FOR the election of all of your Board’s nominees: Brendan M. Cummins, William G. Dempsey, Jay V. Ihlenfeld, Wetteny Joseph, Susan L. Main, Guillermo Novo, Jerome A. Peribere, Ricky C. Sandler, and Janice J. Teal;

   (2)    

Ratification of Ernst & Young LLP (“EY”) as Ashland’s independent registered public accountants for fiscal 2022; and

   (3)    

A non-binding advisory resolution approving the compensation paid to Ashland’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion.

Why am I receiving this Proxy Statement?

Ashland is delivering this Proxy Statement and the accompanying proxy materials to you in connection with the solicitation of proxies by and on behalf of your Board of Directors, for use at the Annual Meeting, which will takes place on Tuesday, January 25, 2022, and at any adjournments and postponements thereof. This Proxy Statement is intended to assist you in making an informed vote on the proposals described in this Proxy Statement. On behalf of our Board of Directors, we are making these materials available to you beginning on or around December 8, 2021 in connection with the solicitation of proxies.

What are the recommendations of the Board of Directors?

Your Board of Directors recommends that you vote your shares as follows:

FOR the election of the directors nominated by your Board of Directors;

FOR the ratification of EY as Ashland’s independent registered public accountants for fiscal year 2022; and

FOR the approval, on a non-binding advisory basis, of the compensation paid to Ashland’s named executive officers.

Who may vote at the Annual Meeting?

Stockholders of Ashland at the close of business on December 1, 2021 (the “Record Date”) are entitled to vote at the Annual Meeting and any adjournments or postponements thereof. As of the Record Date, there were 56,908,383 shares of Common Stock of Ashland (“Ashland Common Stock”) outstanding. Each share of Ashland Common Stock is entitled to one vote.

Who can attend the Annual Meeting?

All Ashland stockholders on the Record Date are invited to attend the Annual Meeting. Due to the current COVID-19 pandemic and in support of the health of our stockholders,

/ efficacy usability allure integrity profitability^™

1

directors and employees, Ashland has determined that the Annual Meeting will be conducted exclusively as a “virtual meeting” of stockholders via online live webcast. There will be no physical location for the meeting. You will be able to attend and listen to the meeting live, submit questions and vote online during the meeting by visiting www.proxydocs.com/ASH. To participate in the Annual Meeting, you will need to register in advance at www.proxydocs.com/ASH prior to the deadline of 10:00 a.m. (EST) on January 25, 2022. Upon completing your registration, you will receive further instructions via email, including your unique links that will allow you access to the Annual Meeting and will also permit you to submit questions.

Why did I receive the Notice of Internet Availability of Proxy Materials in the mail instead of a full set of proxy materials?

In accordance with rules adopted by the Securities and Exchange Commission (the “SEC”), we may furnish proxy materials, including the Notice of Annual Meeting of Stockholders and Proxy Statement, together with our 2021 Annual Report, by providing access to such documents on the Internet instead of mailing printed copies. Most stockholders will not receive printed copies of the proxy materials unless they have specifically requested them. Instead, a Notice of Internet Availability of Proxy Materials (“Notice”) will be mailed to stockholders starting on or around December 13, 2021.

How do I access the proxy materials?

The Notice will provide you with instructions regarding how to view Ashland’s proxy materials for the Annual Meeting and the 2021 Annual Report on the Internet. The Notice also instructs you on how you may submit your vote. If you would like to receive a paper or email copy of our proxy materials, you should follow the instructions for requesting such materials in the Notice.

What shares are included on the proxy card?

If you are a registered stockholder of Ashland as of the Record Date, the proxy card represents all shares of Ashland Common Stock that are registered in your name as well as any shares you hold in the dividend reinvestment plan (the “DRP”) administered by EQ Shareowner Services (“EQ”) for investors in Ashland Common Stock and in the Employee Savings Plan, the Union Plan or the ISP Plan. If your shares are held through a broker, bank or other nominee, your broker, bank or other nominee has enclosed a voting instruction form for you to use to direct it how to vote the shares held by such broker, bank or other nominee. Please return your completed voting instruction form to your broker, bank or other nominee. If your broker, bank or other nominee permits you to provide voting instructions via the Internet or by telephone, you may vote that way as well.

What does it mean if I receive more than one proxy card on or about the same time?

It generally means that you hold shares registered in more than one account. In order to vote all of your shares, please sign, date and return each proxy card or voting instruction form in the postage-paid envelope provided or, if you vote via the Internet or telephone, please be sure to vote using each proxy card or voting instruction form you receive.

How do I vote my shares?

We encourage all stockholders to submit proxies in advance of the Annual Meeting by telephone, by Internet or by mail. Sending your proxy by any of these methods will not affect your right to attend and vote at the Annual Meeting electronically or by executing a proxy designating a representative to vote for you electronically at the Annual Meeting.

/ efficacy usability allure integrity profitability^™

2

How do I vote my shares in the DRP?

The proxy card represents all shares of Ashland Common Stock that are registered in your name as well as any shares you hold in the DRP administered by EQ for investors in Ashland Common Stock. Therefore, you may vote your DRP shares (together with your shares of Ashland common Stock) by (i) attending and voting electronically at the Annual Meeting, (ii) following the instructions on the Notice or proxy card to vote by telephone or Internet or (iii) signing, dating and mailing your proxy card.

How will the Trustee of the Employee Savings Plan, the Union Plan and the ISP Plan vote?

Each participant in the Employee Savings Plan, the Union Plan, or the ISP Plan may instruct the Trustee on how to vote the shares of Ashland Common Stock credited to the participant’s account in each plan. In the case of the Union Plan or the ISP plan, such instructions will additionally be applied to a proportionate number of shares of Ashland Common Stock held in all other plan participants’ accounts for which voting instructions are not timely received by the Trustee (the “non-directed shares”). In the case of the Employee Savings Plan, each participant may separately instruct the Trustee on how to vote a proportionate number of non-directed shares. Each participant who gives the Trustee any such instruction acts as a named fiduciary for the applicable plan under the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). Your vote must be received by the plan tabulator, before 5:00 p.m. (EST) on Friday, January 21, 2022. You may not vote your shares in such plans at the Annual Meeting.

Can I change my vote once I vote by mail, by telephone or over the Internet?

Yes. You have the right to change or revoke your proxy (1) at any time before the Annual Meeting by (a) notifying Ashland’s Secretary in writing at 8145 Blazer Drive, Wilmington, DE 19808, (b) returning a later dated proxy card or (c) entering a later dated telephone or Internet vote; or (2) by voting electronically during the Annual Meeting after registering at www.proxydocs.com/ASH. Any changes or revocations of voting instructions to the Trustee of the Employee Savings Plan, the Union Plan, or the ISP Plan must be received by the plan tabulator, before 5:00 p.m. (EST) on Friday, January 21, 2022.

Who will count the vote?

Representatives of Mediant Communications will tabulate the votes and will act as the inspector of election.

What constitutes a quorum?

As of the Record Date, 56,908,383 shares of Ashland Common Stock were outstanding and entitled to vote. A majority of the shares issued and outstanding and entitled to be voted thereat must be present electronically at the Annual Meeting or by proxy to constitute a quorum to transact business at the Annual Meeting. If you vote electronically at the Annual Meeting, by telephone, over the Internet or by returning a properly executed proxy card, you will be considered a part of that quorum. Abstentions and broker non-votes (if any), as described below, will be treated as present for the purpose of determining a quorum.

/ efficacy usability allure integrity profitability^™

3

What vote is required for approval of each matter to be considered at the Annual Meeting?

A:     

   (1)    

Election of Directors — Under Article V of Ashland’s Certificate of Incorporation (the “Certificate”), the affirmative vote of a majority of votes cast with respect to each director nominee is required for the nominee to be elected. A majority of votes cast means that the number of votes cast “for” a director nominee must exceed the number of votes cast “against” that director nominee.

   (2)    

Ratification of independent registered public accountants — The appointment of EY will be ratified if votes cast in its favor exceed votes cast against it.

   (3)    

Non-binding advisory resolution approving the compensation paid to Ashland’s named executive officers — The non-binding advisory resolution approving the compensation paid to Ashland’s named executive officers, as disclosed in this Proxy Statement pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion, will be approved if the votes cast in its favor exceed the votes cast against it.

What is a broker non-vote?

A broker non-vote occurs when brokers, banks or other nominees holding shares for a beneficial owner have discretionary authority to vote on “routine” matters brought before a stockholder meeting, but the beneficial owner of the shares fails to provide the broker, bank or other nominee with specific instructions on how to vote any “non-routine” matters brought to a vote at the stockholders meeting.

How will my shares be voted if I submit a proxy card but do not specify how I want to vote?

All shares represented by validly executed proxies will be voted at the Annual Meeting, and such shares will be voted in accordance with the instructions provided. If no voting specification is made on your returned proxy card, Guillermo Novo or Yvonne Winkler von Mohrenfels, as individuals named on the proxy card, will vote in line with the Board’s recommendations with respect to any such proposal, i.e., (i) FOR the election of the 9 director nominees, (ii) FOR the ratification of EY, and (iii) FOR the non-binding advisory resolution approving the compensation paid to Ashland’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, compensation tables and narrative discussion.

/ efficacy usability allure integrity profitability^™

4

How will broker non-votes and abstentions be treated?

Ashland will treat broker non-votes as present to determine whether or not there is a quorum at the Annual Meeting, but they will not be treated as entitled to vote on any “non-routine” matters. This means that broker non-votes will have no effect on whether any of the proposals pass. Abstentions will also be treated as present for the purpose of determining quorum, but as unvoted shares for the purpose of determining the approval of the election of directors, the ratification of EY and the approval, on a non-binding advisory basis, of the compensation paid to Ashland’s named executive officers.

Where can I find the voting results of the Annual Meeting?

We intend to announce preliminary voting results based on our proxy solicitor’s advice at the Annual Meeting. We expect to report the final results based on the report of Mediant Communications on a Current Report on Form 8-K filed with the SEC within four business days following the Annual Meeting. You can obtain a copy of the Form 8-K from our website at http://investor.ashland.com, by calling the SEC at 1-800-SEC-0330 for the location of the nearest public reference room or through the SEC’s EDGAR system at http://www.sec.gov.

Who can I contact if I have questions or need assistance in voting my shares, or if I need additional copies of the proxy materials?

Please contact EQ Proxy, the firm assisting us in the solicitation of proxies, toll-free at 1 (833) 656-0643. Banks and brokers may call collect at 1 (516) 220-8356.

Important Notice regarding the availability of Proxy Materials for the

Annual Meeting to be held on January 25, 2022.

This Proxy Statement and Ashland’s 2021 Annual Report to Stockholders are available at

www.ashland.com/proxy.

/ efficacy usability allure integrity profitability^™

5

Name and Address of Beneficial Owner

The Vanguard Group

100 Vanguard Blvd

Malvern, PA 19355

BlackRock, Inc.

55 East 52nd Street

New York, New York 10022

Eminence Capital, LP

399 Park Avenue, 25th Floor

New York, New York 10022

Based on 56,838,804    shares of Ashland Common Stock outstanding as of October 31, 2021.

Based upon information contained in the Schedule 13G/A filed by The Vanguard Group (“Vanguard”) with the SEC on February 10, 2021, Vanguard beneficially owned 5,693,000 shares of Ashland Common Stock as of December 31, 2020 with sole voting power over no shares, shared voting power over 37,161 shares, sole dispositive power over 5,612,015 shares and shared dispositive power over 80,994 shares. Vanguard reported its beneficial ownership on behalf of itself and the following wholly owned subsidiaries: Vanguard Asset Management, Limited; Vanguard Fiduciary Trust Company; Vanguard Global Advisors, LLC; Vanguard Group (Ireland) Limited; Vanguard Investments Australia Ltd.; Vanguard Investments Canada Inc.; Vanguard Investments Hong Kong Limited; and Vanguard Investments UK, Limited.

Based upon information contained in the Schedule 13G/A filed by BlackRock, Inc. (“BlackRock”) with the SEC on January 29, 2021, BlackRock beneficially owned 4,478,998 shares of Ashland Common Stock as of December 31, 2020, with sole voting power over 4,478.998 shares, shared voting power over no shares, sole dispositive power over 4,664,064 shares and shared dispositive power over no shares. BlackRock reported its beneficial ownership on behalf of itself and the following direct and indirect subsidiaries and affiliates: BlackRock Life Limited, BlackRock Advisors, LLC; BlackRock (Netherlands) B.V.; BlackRock Institutional Trust Company, National Association; BlackRock Asset Management Ireland Limited; BlackRock Financial Management, Inc.; BlackRock Asset Management Schweiz AG; BlackRock Investment Management, LLC; BlackRock Investment Management (UK) Limited; BlackRock Asset Management Canada Limited; BlackRock (Luxembourg) S.A.; BlackRock Investment Management (Australia) Limited; BlackRock Advisors (UK) Limited; and BlackRock Fund Advisors.

Based upon information contained in the Schedule 13D/A filed by Eminence Capital LP (“Eminence”) with the SEC on November 18, 2020, Eminence beneficially owned 4,035,178 shares of Ashland Common Stock as of November 16, 2020, with sole voting power over no shares, shared voting power over 4,035,178 shares, sole dispositive power over no shares and shared dispositive power over 4,035,178 shares. Eminence reported its beneficial ownership on behalf of itself and Ricky C. Sandler, a U.S. Citizen (“Mr. Sandler,” and together with Eminence Capital, the “Reporting Persons”). Eminence serves as the management company or investment adviser to and may be deemed to have shared voting and dispositive power over the shares of Common Stock held by, various investment funds and separately managed accounts under its management and control. The general partner of Eminence

/ efficacy usability allure integrity profitability^™

6

is Eminence Capital GP, LLC, the sole managing member of which is Mr. Sandler. Eminence also reported that Mr. Sandler beneficially owned 4,037,968 shares of Ashland Common Stock and 1,454.846 restricted stock units as of November 16, 2020, with sole voting power over 2,790 shares and 1,454.846 restricted stock units, shared voting power over 4,035,178 shares, sole dispositive power over 2,790 shares and 1,454.846 restricted stock units and shared dispositive power over 4,035,178 shares.

/ efficacy usability allure integrity profitability^™

7

Name of Beneficial Owner

 Guillermo Novo

56,408

*

(2)(3)(4)

 J. Kevin Willis

142,334

*

(1)(2)(3)

 Osama M. Musa

22,717

*

(2)(3)

 Min S. Chong

1,790

*

(2)

 Eric N. Boni

29,944

*

(1)(2)(3)

 Peter J. Ganz (a)

80,525

*

(2)(3)

 Keith C. Silverman (a)

5,206

*

(3)

 Brendan M. Cummins

0

—

(2)(4)

 William G. Dempsey

10,855

*

(2)(4)

 Jay V. Ihlenfeld

8,942

*

(2)(4)

 Wetteny Joseph

0

—

 Susan L. Main

7,241

*

(2)(4)

 Jerome A. Peribere

6,368

*

(2)(4)

 Ricky C. Sandler

4,036,664

7.10%

(2)(5)

 Janice J. Teal

28,742

*

(2)(4)

 All directors and executive officers as a group (18 people)

4,446,819

7.79%

(1)(2)(3)(4)(5)

Mr. Ganz left Ashland effective December 31, 2020 and Mr. Silverman left Ashland effective November 20, 2020.

Includes shares of Ashland Common Stock held under the Employee Savings Plan by executive officers: as to Mr. Willis, 33,158 shares; as to Mr. Boni, 7,463 shares; and as to all executive officers as a group, 40,622 shares. Participants can vote the Employee Savings Plan shares.

Includes grants of restricted stock units, common stock units and/or restricted stock units (share equivalents) held by executive officers in the Ashland Common Stock Fund under Ashland’s non-qualified Deferred Compensation Plan for Employees (the “Employees’ Deferral Plan”) or by directors under the non-qualified Deferred Compensation Plan for Non-Employee Directors

/ efficacy usability allure integrity profitability^™

8

(the “Directors’ Deferral Plan”): as to Mr. Novo, 21,466 units; as to Mr. Willis, 33,979 units; as to Dr. Musa, 2,674 units; as to Mr. Chong, 622 units; as to Mr. Boni, 1,920 units; as to Mr. Ganz, 6,374 units; as to Mr. Dempsey, 8,972; as to Dr. Ihlenfeld, 7,059 units; as to Ms. Main, 5,358 units; as to Mr. Peribere, 4,485 units; as to Mr. Sandler, 1,486; as to Dr. Teal, 26,859 units; and as to all directors and executive officers as a group, 122,922. Mr. Cummins, as a non-U.S. resident, is not eligible to defer U.S.-based compensation and therefore holds 21,435 restricted stock units, payable solely in cash, directly and not through the Directors’ Deferral Plan.

Includes shares of Ashland Common Stock with respect to which the executive officers have the right to acquire beneficial ownership within 60 calendar days after October 31, 2021, through the exercise of stock appreciation rights (“SARs”): as to Mr. Novo, 14,044 shares; as to Mr. Willis, 74,371 shares; as to Dr. Musa, 14,677 shares; as to Mr. Chong, 959 shares; as to Mr. Boni, 10,415 shares; and as to all directors and executive officers as a group, 155,071 shares through SARs. All SARs included in this table are reported on a net basis based on the closing price for Ashland Common Stock as reported on the New York Stock Exchange (“NYSE”) Composite Tape on October 31, 2021. All SARs are stock settled and are not issued in tandem with an option.

Includes 1,883 restricted shares of Ashland Common Stock for each of the non-employee directors under the prior director compensation program, except for Mr. Cummins who received 1,883 restricted stock units in lieu of 1,883 restricted shares (discussed in footnote 2 above). Beginning in February 2018, Ashland ceased providing new directors the on-boarding grant of 1,883 restricted shares.

As of October 31, 2021, Mr. Sandler had sole voting power over 2,790 shares and shared voting power over 4,035,178 shares. The 4,035,178 shares (the “Eminence Shares”) were owned by certain funds and investment vehicles (the “Eminence Funds”) managed by Eminence. The Eminence Shares are not held directly by Mr. Sandler. From time to time, certain of these shares are held in the ordinary course of business with other investment securities owned by the Eminence Funds in co-mingled margin accounts with a prime broker that may, from time to time, extend margin credit to certain Eminence Funds, subject to applicable federal margin, stock exchange rules and credit policies. Mr. Sandler is the Founder and Chief Executive Officer/Chief Investment Officer of Eminence, and therefore is in a position to determine the Funds’ investment and voting decisions. Accordingly, Mr. Sandler and Eminence may be deemed to indirectly beneficially own the shares that the Eminence Funds directly and beneficially own. Mr. Sandler beneficially owns 4,037,968 shares and 1,454.846 restricted stock units as of November 16, 2020, with sole voting power over 2,790 shares and 1,454,846 restricted stock units, shared voting power over 4,035,178 shares, sole dispositive power over 2,790 shares and 1,454,846 restricted stock units and shared dispositive power over 4,035,178 shares.

/ efficacy usability allure integrity profitability^™

9

The Board of Directors unanimously recommends a vote FOR ALL the following nominees

at the 2022 Annual Meeting: Brendan M. Cummins, William G. Dempsey, Jay V.  Ihlenfeld,

Wetteny Joseph, Susan L. Main, Guillermo Novo, Jerome A. Peribere,

Ricky C. Sandler and Janice J. Teal.

/ efficacy usability allure integrity profitability^™

10

  BRENDAN M. CUMMINS

Principal Occupation:

Former Consultant to

The Valence Group; Former

Chief Executive Officer of

Ciba Specialty Chemicals

Director Since: 2012

Age: 70

Professional Experience:

Mr. Cummins served as a global strategic advisor to, and on the senior executive panel of, The Valence Group, a specialist mergers and acquisitions firm, from 2010 until May 2012. Prior to that position, Mr. Cummins served as Chief Executive Officer for Ciba Specialty Chemicals (“Ciba”) from 2007 to 2008 and as Chief Operating Officer from 2005 to 2007. From 1974 to 2005, Mr. Cummins held a variety of international and senior management positions with Ciba.

Education:

Mr. Cummins is an Associate and Fellow of the Institute of Company Accountants, is a Fellow of the Association of International Accountants and received a Diploma in Company Direction from the Institute of Directors in 2010. He also completed a management development program at Harvard in 1989.

Other Company Boards:

Mr. Cummins serves as a board member of Perstorp Group Sweden and is a member of the Remuneration Committee and serves on the board of Tom Murphy Car Sales in Ireland. Up until March 2019, he was a board member of Nanoco Group PLC based in Manchester UK where he served as the Senior Independent Director and served as a member of the Audit Committee and Chair of the Remuneration Committee.

Non-Profit Boards:

Mr. Cummins currently serves as a board member and Vice Chairman of Respond Support Ireland, a social housing and a community support charity organization. He also served as Chairman of The Viking Trust Ltd in Waterford City, Ireland from 2012 until July 2016, and as Chair of the Audit Committee and member of the Planning Committee of Waterford City and County Council until the first quarter of 2016.

Director Qualifications:

As the former Chief Executive Officer of a major chemical company and a chemical industry consultant, Mr. Cummins brings significant management and chemical industry experience and knowledge to the Board in the areas of international business operations, accounting and finance, risk oversight, environmental compliance and corporate governance.

Board Committees:

*  Compensation (Chair)

*  Audit

/ efficacy usability allure integrity profitability^™

11

  WILLIAM G. DEMPSEY

Principal Occupation:

Former Executive Vice

President of Global

Pharmaceuticals at Abbott

Laboratories

Director Since: 2016

Age: 70

Professional Experience:

Mr. Dempsey held various executive positions with Abbott Laboratories from 1982 until 2007, including Executive Vice President of Global Pharmaceuticals from 2006, Senior Vice President of Pharmaceutical Operations from 2003 and Senior Vice President of International Operations from 1999. He has previously served as Chairman of the International Section of the Pharmaceutical Research and Manufacturers of America (PhRMA) and as Chairman of the Accelerating Access Initiative, a cooperative public-private partnership of UNAIDS, the World Bank, and six research-based pharmaceutical companies.

Education:

Mr. Dempsey holds a Bachelor of Science degree in accounting from DePaul University.

Public Company Boards:

Mr. Dempsey currently serves as non-executive Chairman of the Board of Hill-Rom Holdings, Inc., where he is Chair of the Mergers and Acquisitions Committee and a member of the Nominating and Governance Committee. In the past five years, Mr. Dempsey has served on the board of Landauer, Inc. From March 2018 to July 2018, Mr. Dempsey served as Executive Chairman of Hill-Rom Holdings, Inc.

Non-Profit Boards:

Mr. Dempsey is a member of the Board of Trustees for the Guadalupe Center in Immokalee Florida.

Director Qualifications:

As former Executive Vice President of Global Pharmaceuticals at a public company, Mr. Dempsey brings significant experience within the pharmaceutical industry, as well as knowledge in the areas of finance, accounting, international operations and corporate governance. He also brings significant experience gained from service on the boards of other public companies.

Board Committees:

*  Governance and Nominating (Chair)

*  Environmental, Health, Safety and Quality

/ efficacy usability allure integrity profitability^™

12

  JAY V. IHLENFELD

Principal Occupation:

Former Senior Vice President

of 3M Company

Director Since: 2017

Age: 69

Lead Independent Director

Professional Experience:

Dr. Ihlenfeld served as the Senior Vice President, Asia Pacific, for 3M Company, a leader in technology and innovation, from 2006 until his retirement in 2012. Dr. Ihlenfeld has held various leadership positions during his 33-year career at 3M Company, including Senior Vice President, Research and Development from 2002 to 2006, Vice President of its Performance Materials business and Executive Vice President of its Sumitomo/3M business in Japan.

Education:

Dr. Ihlenfeld holds a Bachelor of Science degree in chemical engineering from Purdue University and a Ph.D. in chemical engineering from the University of Wisconsin.

Public Company Boards:

Dr. Ihlenfeld is a director of Celanese Corporation, where he serves on the Compensation and Management Development Committee and is the chair of the Environmental, Health, Safety, Quality and Public Policy Committee.

Non-Profit Boards:

Dr. Ihlenfeld is a director of the Minnesota Orchestra and is currently serving on the Executive Committee and Chair of the Audit Committee. Dr. Ihlenfeld is also Vice President and Trustee of Phi Delta Theta Foundation.

Director Qualifications:

As a former Senior Vice President of a global science company, Dr. Ihlenfeld brings significant management and chemical industry experience to the Board, as well as knowledge in the areas of international operations, leadership development and succession, environmental compliance and safety, risk oversight and M&A evaluation. He also brings significant experience gained from service on the board of directors of another public company.

Board Committees:

*  Compensation

*  Environmental, Health, Safety and Quality

  WETTENY JOSEPH

Principal Occupation:

Executive Vice President and

Chief Financial Officer of

Zoetis, Inc.

Director Since: 2021

Age: 49

Professional Experience:

Mr. Joseph is the Executive Vice President and Chief Financial Officer of Zoetis, Inc. (“Zoetis”), an American drug company and the world’s largest producer of medicines and vaccinations for pets and livestock since June 2021. Prior to that, Mr. Joseph held various leadership positions within Catalent from 2008 to 2021, including Senior Vice President and Chief Financial Officer between 2018 and 2021; President, Clinical Supply Services from 2015 to 2018; and Vice President, Finance in various capacities from 2008 to 2012.

Education:

Mr. Joseph holds a Bachelor of Science degree and a Master of Accounting degree both from Florida Atlantic University.

Director Qualifications:

As the Executive Vice President and Chief Financial Officer of Zoetis, Mr. Joseph brings significant management and life sciences industry experience to the Board, as well as knowledge in the areas of public company finance, accounting, business strategy, business operations, and international operations.

Board Committees:

*  Audit

*  Environmental, Health, Safety and Quality

/ efficacy usability allure integrity profitability^™

13

  SUSAN L. MAIN

Principal Occupation:

Senior Vice President and

Chief Financial Officer of

Teledyne Technologies

Incorporated

Director Since: 2017

Age: 63

Professional Experience:

Ms. Main is Senior Vice President and Chief Financial Officer of Teledyne Technologies, Inc., a leading provider of digital imaging products and software, sophisticated instrumentation, aerospace and defense electronics, and engineered systems, since November 2012. Prior to that, she was Vice President and Controller of Teledyne, a position she held for eight years. From 1999 to 2004, Ms. Main served as Vice President and Controller for Water Pik Technologies, Inc. She also held numerous financial roles at the former Allegheny Teledyne Incorporated in its government, industrial and commercial segments.

Education:

Ms. Main holds a Bachelor of Arts degree in Business Administration from California State University, Fullerton.

Public Company Boards:

Ms. Main was a director of Garrett Motion Inc. between October 2018 and April 2021 and served as a member of the Audit and Nominating and Corporate Governance committees.

Director Qualifications:

As the Senior Vice President and Chief Financial Officer of a public company, Ms. Main brings significant management and public company financial experience and knowledge to the Board in the areas of finance, accounting, operations, risk oversight and corporate governance. She also brings experience gained from service on the board of directors of another public company.

Board Committees:

*  Audit (Chair)

*  Governance and Nominating

/ efficacy usability allure integrity profitability^™

14

  GUILLERMO NOVO

Principal Occupation:

Chairman of the

Board and Chief Executive Officer of Ashland Global Holdings Inc.

Director Since: 2019

Age: 59

Professional Experience:

Mr. Novo is Ashland’s Chairman of the Board and Chief Executive Officer. Prior to that position, Mr. Novo served as the President and CEO of Versum Materials, Inc., and was a member of the board of directors. Previously, Mr. Novo served as Executive Vice President, Materials Technologies of Air Products and Chemicals, Inc. (“Air Products”) since October 2014. He joined Air Products in September 2012 as Senior Vice President Electronics, Performance Materials, Strategy and Technology. Prior to joining Air Products, Mr. Novo was employed by the Dow Chemical Company where he most recently served as group vice president, Dow Coating Materials, a large specialty chemicals business. He began his career in 1986 with Rohm and Haas Company (which merged with Dow in 2009) and over the next 24 years progressed through a variety of commercial, marketing, and general management positions, living in South America, the United States and Asia. In 1998, Mr. Novo was named a vice president at Rohm and Haas, and in 2006 he became a corporate officer and one of five group executives on the corporate leadership team responsible for driving the overall strategy for the company.

Education:

Mr. Novo holds a Bachelor of Science degree in industrial engineering from the University of Central Florida and a Master of Business Administration degree from the University of Michigan.

Public Company Boards:

Mr. Novo is a director of PPG Industries, Inc. since February 2021 and serves on the Audit and Compensation Committees. Mr. Novo has served as a director of Ashland since May 22, 2019, serving on the Audit Committee until October 8, 2019 and serving on the Environmental, Health, Safety and Quality Committee until December 31, 2019. Within the past five years, Mr. Novo served as a director of Versum Materials, Inc. and Bemis Company, where he served on the Compensation and Nominating and Governance committees.

Director Qualifications:

As the Chairman and Chief Executive Officer of Ashland and as the former President and Chief Executive Officer of Versum Materials, Inc., a leading electronic materials company, Mr. Novo brings over thirty years of leadership experience in the specialty materials and specialty chemicals industries. With his public company and leadership roles, he brings significant experience and knowledge to the Board in the areas of business strategy, business operations, manufacturing, safety, management, finance, accounting, risk oversight and corporate governance. Mr. Novo also brings substantial experience gained from service on the board of directors of other public companies.

/ efficacy usability allure integrity profitability^™

15

  JEROME A. PERIBERE

Principal Occupation:

Former President and Chief

Executive Officer of

Sealed Air Corporation

Director Since: 2018

Age: 67

Professional Experience:

Mr. Peribere was the President and Chief Executive Officer of Sealed Air Corporation (“Sealed Air”) from March 2013 until his retirement in December 2017. Prior to this position, he served as the President and Chief Operating Officer of Sealed Air. Prior to joining Sealed Air, Mr. Peribere worked at The Dow Chemical Company (“Dow”) from 1977 through August 2012. Mr. Peribere served in multiple managerial roles with Dow, most recently as Executive Vice President of Dow and President and Chief Executive Officer, Dow Advanced Materials, a unit of Dow, from 2010 through August 2012.

Education:

Mr. Peribere holds a degree in business economics and finance from the Institut D’Etudes Politiques in Paris, France.

Public Company Boards:

Mr. Peribere is a director of Xylem Inc. where he serves on the Audit Committee and chairs the Leadership Development and Compensation Committee. Mr. Peribere previously served as a director of Sealed Air and BMO Financial Corporation.

Director Qualifications:

As the former President and Chief Executive Officer of Sealed Air and former Executive Vice President of Dow and President and Chief Executive Officer of Dow Advanced Materials, Mr. Peribere brings significant management and chemical industry experience and knowledge to the Board in the areas of finance, international business operations, safety, environmental compliance, risk oversight and corporate governance. He also brings significant experience gained from service on the board of directors of other public companies.

Board Committees:

*  Compensation

*  Governance and Nominating

/ efficacy usability allure integrity profitability^™

16

  RICKY C. SANDLER

Principal Occupation:

Founder and Chief Executive

Officer/Chief Investment

Officer of Eminence Capital

Director Since: 2020

Age: 52

Professional Experience:

In 1999 Mr. Sandler founded Eminence Capital, LP (“Eminence”), a global investment management organization with more than $8 billion under management. As the Chief Executive Officer and Chief Investment Officer of Eminence, Mr. Sandler is responsible for managing a team of investment professionals and a diversified portfolio across most sectors of the equity market. Prior to launching Eminence, Mr. Sandler was co-founder and co-general partner of Fusion Capital Management, LLC. Previously, he was a research analyst covering a wide range of industries and companies for Mark Asset Management, where he began his investing career in 1991.

Education:

Mr. Sandler holds a Bachelor of Business Administration degree in accounting and finance from the University of Wisconsin. He has also received his Chartered Financial Analyst designation from the CFA Institute.

Non-Profit Boards:

Mr. Sandler serves on the boards of two small non-profit companies.

Director Qualifications:

Mr. Sandler brings more than 25 years of business and investment experience to the Board. He brings a unique institutional investor perspective, including strong relationships with other investors and stockholders, to the Board and can provide critical insight on issues most important to Ashland’s stockholders. As a result of his role at Eminence, he brings extensive experience and knowledge in the areas of finance, business strategy, accounting, risk oversight and corporate governance.

Board Committees:

*  Audit

*  Governance and Nominating

  JANICE J. TEAL

Principal Occupation:

Former Group Vice

President and Chief

Scientific Officer for

Avon Products Inc.

Director Since: 2012

Age: 69

Professional Experience:

Dr. Teal served as the Group Vice President and Chief Scientific Officer for Avon Products Inc., a direct seller of beauty and related products, from January 1999 to May 2010. Prior to that position, Dr. Teal served as Vice President of the Avon Skin Care Laboratories, where she led the bioscience research and skin care teams.

Education:

Dr. Teal holds a doctorate degree and a Master of Science degree in pharmacology from Emory University Medical School, a pharmacy degree from Mercer University and was a post-doctoral fellow at the New York University Medical Center Institute of Environmental Medicine.

Public Company Boards:

From 2003 until 2011, Dr. Teal served as a director of Arch Chemicals, Inc., where she served on the Audit Committee and the Corporate Governance Committee.

Non-Profit Boards:

Dr. Teal serves on the Board of Trustees of Naples Community Hospital Healthcare System.

Director Qualifications:

As former Group Vice President and Chief Scientific Officer of a leading personal care company, Dr. Teal brings significant scientific and personal care industry experience and knowledge to the Board in the areas of research and development, marketing, safety and risk oversight. She also brings significant experience gained from service on the board of directors of another public chemical company.

Board Committees:

*  Environmental, Health, Safety and Quality (Chair)

*  Compensation

/ efficacy usability allure integrity profitability^™

17

 African American

 Asian/Pacific Islander

 White/Caucasian

 Hispanic/Latino

 Native American

 GENDER

 Male

 Female

 TENURE⁽¹⁾

Counting the start year and 2021 as full years.

/ efficacy usability allure integrity profitability^™

18

Committee Role

Director Retainer

Lead Independent Director

Audit Committee Chair

All Other Committee Chairs

Name

Brendan M. Cummins

William G. Dempsey

Jay V. Ihlenfeld

Wetteny Joseph (3)

Susan L. Main

Jerome A. Peribere

Craig A. Rogerson (4)

Ricky C. Sandler

Janice J. Teal

/ efficacy usability allure integrity profitability^™

19

For fiscal 2021 Mr. Dempsey, Mr. Joseph and Dr. Teal deferred all or a portion of their fees into the Directors’ Deferral Plan. Mr. Dempsey deferred $28,750, Mr. Joseph deferred $50,000 and Dr. Teal deferred $115,000.

The values in column (c) represent the aggregate grant date fair value of restricted stock unit awards granted in fiscal 2021 computed in accordance with FASB ASC Topic 718. These restricted stock unit awards do not require assumptions in computing their grant date fair value under generally accepted accounting principles. The number of restricted stock unit awards received is rounded to the nearest whole share. Other than Mr. Cummins, each continuing non-employee director received a grant of 1,319 restricted stock units of Ashland Common Stock in the Directors’ Deferral Plan on January 26, 2021. The grant date fair value per share of each restricted stock unit was $83.37 per share of Ashland Common Stock. Mr. Cummins received 1,319 restricted stock units on such date, which was based on the grant date fair value of $83.37 per share of Ashland Common Stock.

Mr. Joseph joined the Board on January 26, 2021.

Mr. Rogerson did not stand for reelection to the Board at the Annual Meeting of Stockholders on January 28, 2021.

Name

Brendan M. Cummins

William G. Dempsey

Jay V. Ihlenfeld

Susan L. Main

Wetteny Joseph

Jerome A. Peribere

Ricky C. Sandler

Janice J. Teal

Includes credit for reinvested dividends allocated since the grant date for all directors. For all directors other than Mr. Cummins, the restricted stock units vest one year after date of grant. Mr. Cummins’ restricted stock units vest as described below under the section entitled “Restricted Stock Units” of this Proxy Statement.

/ efficacy usability allure integrity profitability^™

20

/ efficacy usability allure integrity profitability^™

21

Ashland has adopted Corporate Governance Guidelines. These guidelines provide the framework for the Board’s governance of Ashland and include a general description of the Board’s purpose, director qualification standards, retirement and resignation policies and other responsibilities. The Corporate Governance Guidelines require that at least two-thirds of Ashland’s directors be independent, as defined by Ashland’s Director Independence Standards (the “Standards”), which incorporate the independence requirements of the SEC rules and the listing standards of the NYSE.

Ashland also requires compliance with its global code of conduct which applies to all of Ashland’s directors and employees, including the principal executive officer, principal financial officer, principal accounting officer and persons performing similar functions. The global code of conduct promotes honest and ethical conduct, compliance with applicable laws, rules and regulations, prompt reporting of violations of the code and full, fair, accurate, timely and understandable disclosure in reports filed with the SEC. Ashland intends to post any amendments or waivers of the code (to the extent applicable to Ashland’s directors and executive officers) on Ashland’s website or in a Current Report on Form 8-K.

Each of Ashland’s Board Committees has adopted a charter defining its respective purposes and responsibilities. Ashland has a separately designated standing audit committee established in accordance with Section 3(a)(58)(A) of the Exchange Act.

Only independent directors, as defined in the Standards, may serve on the Audit Committee, G&N Committee, and Compensation Committee of the Board.

The Board, and each Committee of the Board, has the authority to engage independent consultants and advisors.

/ efficacy usability allure integrity profitability^™

22

Coordinates with the Chairman of the Board to determine the appropriate schedule of meetings;

Places any item he or she determines is appropriate on the Board’s agenda;

Directs that specific materials be included in Board mailings and works with the G&N Committee, as appropriate, to assess the quality, quantity and timeliness of the flow of information from management to the Board;

Directs the retention of consultants and advisors to report directly to the Board;

Coordinates with the G&N Committee to oversee compliance with Ashland’s Corporate Governance Guidelines and to recommend appropriate revisions thereto;

Coordinates and develops the agenda for, and moderates executive sessions of, the Board’s independent directors and acts as principal liaison between the independent directors and the Chairman of the Board and Chief Executive Officer on sensitive matters; and

Works with the G&N Committee to recommend the membership of the various Board Committees and Committee Chairs.

Ensure that the Company’s executive compensation programs are competitive, support organizational objectives and stockholder interests, and emphasize the pay-for-performance linkage;

Review, evaluate and approve on an annual basis, the goals and objectives of the Chief Executive Officer. The Compensation Committee annually evaluates the Chief Executive Officer’s performance in light of these established goals and objectives, and based on these evaluations, the Compensation Committee sets the Chief Executive Officer’s annual compensation, including base salary, annual incentives and long-term incentives;

Review and approve compensation of all executive officers who are “officers” under Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”); and

Approve any employment agreements, consulting arrangements, severance or retirement arrangements, change in control agreements, and/or any special or supplemental benefits or provisions covering any current or former executive officer of Ashland.

/ efficacy usability allure integrity profitability^™

23

Recommendations of the Chief Executive Officer and human resources regarding potential changes to executive officer compensation based on performance, competitiveness, personnel and organizational changes, regulatory issues, strategic initiatives and other matters;

Information provided by human resources function at Ashland; and

Advice of an outside, independent, executive compensation consultant on all aspects of executive compensation, including comparison to the practices and executive compensation levels of peer and general industry companies.

/ efficacy usability allure integrity profitability^™

24

/ efficacy usability allure integrity profitability^™

25

Compensation to a director or executive officer which is or will be disclosed in Ashland’s proxy statement;

Compensation to an executive officer which is approved by the Compensation Committee and would have been disclosed in Ashland’s proxy statement if the executive officer was a “named executive officer”;

A transaction in which the rates or charges involved are determined by competitive bids, or which involves common, contract carrier or public utility services at rates or charges fixed in conformity with law or governmental authority;

A transaction that involves services as a bank depository of funds, transfer agent, registrar, indenture trustee or similar services; and

A transaction in which the related person’s interest arises solely from the ownership of Ashland Common Stock and all stockholders receive the same benefit on a pro rata basis.

/ efficacy usability allure integrity profitability^™

26

as to each stockholder proposing a nominee and any Stockholder Associated Person (as defined below),

the class or series and number of shares of stock directly or indirectly held of record and beneficially by the stockholder proposing such business or Stockholder Associated Person;

/ efficacy usability allure integrity profitability^™

27

the date such shares of stock were acquired;

a description of any agreement, arrangement or understanding, direct or indirect, with respect to such business between or among the stockholder proposing such business, any Stockholder Associated Person or any others (including their names) acting in concert with any of the foregoing;

a description of any agreement, arrangement or understanding (including any derivative or short positions, profit interests, options, hedging transactions and borrowed or loaned shares) that has been entered into, directly or indirectly, as of the date of such stockholder’s notice by, or on behalf of, the stockholder proposing such business or any Stockholder Associated Person, the effect or intent of which is to mitigate loss to, manage risk or benefit of share price changes for, or increase or decrease the voting power of the stockholder proposing such business or any Stockholder Associated Person with respect to shares of stock of Ashland (a “Derivative”);

a description in reasonable detail of any proxy (including revocable proxies), contract, arrangement, understanding or other relationship pursuant to which the stockholder proposing such business or Stockholder Associated Person has a right to vote any shares of stock of Ashland;

any rights to dividends on the stock of Ashland owned beneficially by the stockholder proposing such business or Stockholder Associated Person that are separated or separable from the underlying stock of Ashland;

any proportionate interest in stock of Ashland or Derivatives held, directly or indirectly, by a general or limited partnership in which the stockholder proposing such business or Stockholder Associated Person is a general partner or, directly or indirectly, beneficially owns an interest in a general partner; and

any performance-related fees (other than an asset-based fee) that the stockholder proposing such business or Stockholder Associated Person is entitled to, based on any increase or decrease in the value of stock of Ashland or Derivatives thereof, if any, as of the date of such notice (sections (i) through (viii), the “Stockholder Information”);

as to each stockholder proposing such nominee, the name and address of (i) any other beneficial owner of stock of Ashland that are owned by such stockholder and (ii) any person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, the stockholder or such beneficial owner (each, a “Stockholder Associated Person”);

the name and address of each stockholder proposing such nominee, as they appear on Ashland’s books;

the name and address of the person or persons to be nominated;

a representation that the stockholder is a holder of record of stock of Ashland entitled to vote in the election of directors and intends to appear in person or by proxy at the meeting;

a description of all arrangements or understandings between the stockholder and each nominee and any other person or persons (naming such person or persons) pursuant to which the nomination or nominations are to be made by the stockholder;

a description of all direct and indirect compensation and other material monetary agreements, arrangements and understandings during the past three years, and any other material relationships, between or among the stockholder and any Stockholder Associated Person or any of their respective affiliates or associates or other parties with whom they are acting in concert, including all information that would be required to be disclosed pursuant to Rule 404 promulgated under Regulation S-K if the stockholder, Stockholder Associated Person or any person acting in concert therewith, were the

/ efficacy usability allure integrity profitability^™

28

“registrant” for purposes of such rule and each nominee were a director or executive of such registrant;

such other information regarding each nominee proposed by such stockholder and Stockholder Associated Persons as would have been required to be included in a proxy statement filed pursuant to the proxy rules of the SEC had each nominee been nominated, or intended to be nominated, by the Board and a completed signed questionnaire, representation and agreement required by Section 3.02(c) of Ashland’s By-laws;

a representation as to whether such stockholder intends (a) to deliver a proxy statement and form of proxy to holders of at least the percentage of Ashland’s outstanding capital stock required to approve the nomination or (b) otherwise to solicit proxies from stockholders in support of such nomination;

a representation that the stockholder shall provide any other information reasonably requested by Ashland; and

the executed written consent of each nominee to serve as a director of Ashland if so elected.

/ efficacy usability allure integrity profitability^™

29

Audit

Compensation

Environmental, Health,

Safety and Quality

Governance and

Nominating

Chair

 Audit Committee

Number of Meetings in Fiscal 2021: 8

Oversees Ashland’s financial reporting process, including earnings releases and the filing of financial reports.

Reviews management’s implementation and maintenance of adequate systems of internal accounting and financial controls (including internal control over financial reporting).

Evaluates the independence and performance of the independent auditors, who report directly to the Audit Committee.

Selects independent auditors based on qualification and independence and approves audit fees and services performed by independent auditors.

Reviews the effectiveness of Ashland’s legal and regulatory compliance programs.

Discusses the overall scope and plans for audits with both internal and independent auditors.

Reviews and investigates any matters pertaining to the integrity of executive management and oversees compliance by management with laws, regulations and the global code of conduct.

Establishes and maintains procedures for handling complaints regarding accounting and auditing matters.

Reviews and oversees Ashland’s capital allocation framework, including prioritization, significant decisions and risk considerations relating to Ashland’s financial resources, capital structure and investments and uses of cash.

Reviews Ashland’s enterprise risk assessment and risk management policies, including Ashland’s major enterprise and financial risk exposures and steps taken by management to monitor and mitigate such exposures.

Evaluates and recommends actions regarding significant financial issues such as capital structure, dividend policy, offerings of corporate securities, major borrowings, credit facilities, derivatives and swaps policies (including entry into swaps in reliance on the end-user exception), past audits of capital investments, capital projects, commercial commitments and merger, acquisition and divestiture activities.

/ efficacy usability allure integrity profitability^™

30

Oversees funding and investment policy related to employee benefit plans.

Reviews performance and operation of internal audit, including the head of internal audit, and reviews adverse audit reports.

Reviews the Company’s information and cyber security risks and programs.

 Compensation Committee

Number of Meetings in Fiscal 2021: 5

Ensures Ashland’s executive compensation programs are appropriately competitive, supports organizational objectives and stockholder interests and emphasizes pay for performance linkage.

Evaluates and approves compensation and sets performance criteria for compensation programs with respect to Ashland’s Chief Executive Officer.

Evaluates and approves compensation and sets performance criteria for compensation programs for all executive officers subject to Section 16 of the Exchange Act.

Oversees the execution of Chief Executive Officer and senior management development and succession plans, including HR-related business continuity plans.

Approves any employment agreements, consulting arrangements, severance or retirement arrangements, change in control agreements and/or any other special or supplemental benefits covering any current or former executive officer.

Adopts, amends, terminates and performs other design functions for Ashland’s benefit plans.

Oversees the implementation and administration of Ashland’s compensation plans.

Monitors and evaluates Ashland’s compensation and benefits structure, providing guidance on philosophy, policy matters and excessive risk taking.

Oversees regulatory compliance on compensation matters, including Ashland’s policies on structuring compliance programs to preserve tax deductibility.

Oversees the preparation of the annual report on executive compensation.

Oversees the retention of compensation consultants, independent legal counsel or other advisors and determines independence of the same.

 Environmental, Health, Safety and Quality Committee

Number of Meetings in Fiscal 2021: 4

Oversees and reviews Ashland’s environmental, health and safety, quality and compliance policies, programs, practices and audits and any issues, as well as competitors’ activities and industry best practices.

Oversees and reviews environmental, health and safety regulatory trends, including Ashland’s overall compliance, remediation and sustainability efforts.

Oversees and reviews product safety and quality trends, issues and concerns which affect or could affect Ashland’s product safety or quality practices, including Ashland’s overall efforts related to product safety and quality.

Oversees, reviews and receives updates on Ashland’s policies regarding environmental, health, safety and quality compliance and business continuity risks.

Reports to the Board concerning implementation of environmental, health, safety and quality compliance policies and assists the Board in assuring Ashland’s compliance with those policies.

 Governance and Nominating Committee

Number of Meetings in Fiscal 2021: 5

Recommends nominees for the Board of Directors and its Committees.

Reviews suggested potential candidates for the Board.

/ efficacy usability allure integrity profitability^™

31

Recommends desirable size and composition of the Board and its Committees.

Recommends to the Board programs and procedures relating to director compensation, evaluation, retention and resignation.

Reviews corporate governance guidelines, corporate charters and proposed amendments to Ashland’s Certificate of Incorporation and By-laws.

Reviews transactions pursuant to the Related Person Transaction Policy.

Assists the Board in ensuring the Board’s independence as it exercises its corporate governance and oversight roles.

Oversees the evaluation of the Board.

Reviews the process for succession planning for the executive management of Ashland.

Reviews all Committee charters.

Reviews and makes recommendations to address stockholder proposals.

Oversees the administration of the equity plans and awards, solely with respect to non-employee directors.

/ efficacy usability allure integrity profitability^™

32

Name

Title

On December 31, 2020, Mr. Ganz retired from the Company

On November 20, 2020, Mr. Silverman left the company due to company reorganization

Ashland signed a definitive sale agreement with Arkema on August 31, 2021 to sell the Performance Adhesives business for $1.65 billion. Expected net proceeds are $1.2 to $1.3 billion and the transaction is expected to close in the March quarter of 2022.

In September 2021, Ashland established a renewable annual trust for environmental remediation (Environmental Trust) that Ashland determined is restricted for ongoing and future environmental remediation and related litigation costs. The initial funding of this trust was $90 million.

In September 2021, under the 2018 stock repurchase program, Ashland announced that it entered into an accelerated share repurchase agreement (2021 ASR Agreement). Under the 2021 ASR Agreement, Ashland paid an initial purchase price of $450 million and received an initial delivery of 3.9 million shares of common stock during September 2021. The program is expected to terminate by March 2022, resulting in a final share repurchase transaction.

In April 2021, Ashland completed its acquisition of the personal care business of Schülke & Mayr GmbH (Schülke), a portfolio company of the global investment organization EQT. Ashland has included the purchase of this business within the Personal Care and Household reporting segment. The all-cash purchase price of Schülke was $312 million. The

/ efficacy usability allure integrity profitability^™

33

completion of the acquisition strengthens the profitable growth of the personal care and household business segment, enhances the specialty ingredients solutions and expands the biotechnology and microbiology technical competencies.

Operating income of $181 million in 2021 compared to a loss of $463 million in 2020. The 2020 loss was driven by a $530 million goodwill impairment charge associated with Ashland’s business realignment during fiscal 2020 and is also included in the loss from continuing operations and net loss for fiscal 2020 discussed below.

Income from continuing operations of $173 million in 2021 compared to a loss of $555 million in 2020.

Net income of $220 million in 2021 compared to a loss of $508 million in 2020.

Adjusted EBITDA of $495 million in 2021 compared to $449 million in 2020.

(In millions) $

Sales

Life Science

Personal Care & Household

Specialty Additives

Intermediates and Solvents

Intersegment sales

Operating Income (Loss)

Life Sciences

Personal Care & Household

Specialty Additives

Intermediates and Solvents

Unallocated and other

EBITDA (1)

Life Sciences

Personal Care & Household

Specialty Additives

Intermediates and Solvents

Unallocated and other

/ efficacy usability allure integrity profitability^™

34

(In millions) $

Adjusted EBITDA (1)

Life Sciences

Personal Care & Household

Specialty Additives

Intermediates and Solvents

Unallocated and other

EBITDA and Adjusted EBITDA are non-GAAP measures and are reconciled to net income for Ashland and operating income for each segment in Appendix A.

/ efficacy usability allure integrity profitability^™

35

Align the interests of management with our stockholders

To closely align the interests of management with the interests of our stockholders, a significant portion of each executive’s compensation is equity-based and is linked to building long-term stockholder value through the achievement of the financial and strategic objectives of Ashland.

Provide incentive compensation that promotes desired behavior without encouraging unnecessary and excessive risk

Incentive compensation should help drive business strategy. The compensation program should encourage both the desired results and the right behaviors. It should help drive business strategy and strike a balance between short-term and long-term performance, while incorporating risk-mitigating design features so that unnecessary or excessive risk is not encouraged.

Attract, retain and motivate executive talent by providing competitive levels of salary and targeted total pay

Compensation should be competitive with those organizations with which we compete for top talent and attract and retain executive officers with the skills, experience and motivation to achieve stated Company objectives.

Integrate with our performance management process of goal-setting and formal evaluation

Target-level goals should be aligned with the annual operating plan and be considered stretch yet achievable, based on an annual assessment of business conditions for the performance period.

Be straightforward and transparent in its design

Clearly describe all elements of our executive compensation programs, individually and in the aggregate, for our shareholders and other interested parties.

/ efficacy usability allure integrity profitability^™

36

Base Salary

Annual Incentive

PSUs

RSUs

Recipient

When Granted /

Received or Reviewed

Form of Delivery

Compensation Committee judgment based on review of market and other factors

Formulaic; Compensation Committee verifies performance before payout

Formulaic; Compensation Committee verifies performance before payout

Stock price on vest

date

Stock price appreciation

Deliver on long-term strategic objectives; outperform peers

Balance

against excessive risk-taking and retention

Adjusted EBITDA and EBITDA Margin, in each case, as used for purposes of our Annual Incentive Plan, and Adjusted RONA, as used for purposes of our Long-Term Incentive Performance Plan, are non-GAAP measures. Other than Adjusted RONA, a reconciliation of these measures to results in accordance with GAAP can be found in Appendix A. Adjusted RONA is a non-GAAP measure and will be reconciled when the long-term incentive performance plan is scored.

/ efficacy usability allure integrity profitability^™

37

Considerations used to choose peer group

   How we use peer group information

✓  Comparable revenue size

✓  Global operations

✓  Industry

✓  Market capitalization

✓    _{Input in developing base salary ranges, annual incentive target opportunities and long-term incentive awards}

✓    Assess competitiveness of total direct compensation

✓    Determine form and mix of equity

✓   Input to designing compensation plans,   benefits and perquisites

    Sensient Technologies

      Corporation

    International Flavors &

      Fragrances, Inc.